Tools
Tools
Kujawska, Magdalena, Neuhaus, Klaus, Huptas, Christopher, Jiménez, Esther, Arboleya, Silvia, Schaubeck, Monika and Hall, Lindsay J. 
ORCID: https://orcid.org/0000-0001-8938-5709
(2024)
Exploring the potential probiotic properties of Bifidobacterium breve DSM 32583—A novel strain isolated from human milk.
Probiotics and Antimicrobial Proteins.
ISSN 1867-1306
Abstract
Human milk is the best nutrition for infants, providing optimal support for the developing immune system and gut microbiota. Hence, it has been used as source for probiotic strain isolation, including members of the genus Bifidobacterium, in an effort to provide beneficial effects to infants who cannot be exclusively breastfed. However, not all supplemented bifidobacteria can effectively colonise the infant gut, nor confer health benefits to the individual infant host; therefore, new isolates are needed to develop a range of dietary products for this specific age group. Here, we investigated the beneficial potential of Bifidobacterium breve DSM 32583 isolated from human milk. We show that in vitro B. breve DSM 32583 exhibited several characteristics considered fundamental for beneficial bacteria, including survival in conditions simulating those present in the digestive tract, adherence to human epithelial cell lines, and inhibition of growth of potentially pathogenic microorganisms. Its antibiotic resistance patterns were comparable to those of known beneficial bifidobacterial strains, and its genome did not contain plasmids nor virulence-associated genes. These results suggest that B. breve DSM 32583 is a potential probiotic candidate. Graphical Abstract: (Figure presented.)
| Item Type: | Article |
|---|---|
| Additional Information: | Data Availability Statement: No datasets were generated or analysed during the current study. Funding Information: Financial interests: Lindsay Hall and Klaus Neuhaus report financial support provided by HiPP GmbH und Co Vertrieb KG. Monika Schaubeck reports a relationship with HiPP GmbH und Co Vertrieb KG that includes employment. Monika Schaubeck has patent pending to HiPP & Co. Esther Jim\u00E9nez is employee of Probisearch, SLU, a company that received funding from HiPP GmbH & Co. Vertrieb KG, Pfaffenhofen, Germany, to perform phenotypic characterisation experiments and data analysis. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. |
| Uncontrolled Keywords: | bifidobacterium breve,human milk,infant microbiome,probiotic,microbiology,molecular medicine,molecular biology,sdg 3 - good health and well-being ,/dk/atira/pure/subjectarea/asjc/2400/2404 |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 25 Oct 2024 10:30 |
| Last Modified: | 01 Nov 2024 13:30 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/97204 |
| DOI: | 10.1007/s12602-024-10346-9 |
Actions (login required)
 |
View Item |